Supply Chain Management in the Drug Industry
- 0 %
Der Artikel wird am Ende des Bestellprozesses zum Download zur Verfügung gestellt.

Supply Chain Management in the Drug Industry

Delivering Patient Value for Pharmaceuticals and Biologics
 E-Book
Sofort lieferbar | Lieferzeit: Sofort lieferbar I
ISBN-13:
9780470922842
Veröffentl:
2011
Einband:
E-Book
Seiten:
458
Autor:
Hedley Rees
eBook Typ:
EPUB
eBook Format:
Reflowable E-Book
Kopierschutz:
Adobe DRM [Hard-DRM]
Sprache:
Englisch
Beschreibung:

This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials. The author suggests that CMC (chemistry manufacturing controls) drug development must reset the line of sight from supply of drug to the clinic and gaining a registration, to the building of a patient value stream. Capable processes and suppliers, streamlined logistics, flexible plant and equipment, shorter cycle times, effective flow of information and reduced waste. All these factors can and should be addressed at the CMC development stage.
This book bridges the gap between practitioners of supply-chainmanagement and pharmaceutical industry experts. It aims to helpboth these groups understand the different worlds they live in andhow to jointly contribute to meaningful improvements insupply-chains within the globally important pharmaceutical sector.Scientific and technical staff must work closely with supply-chainpractitioners and other relevant parties to help secure responsivecost effective and risk mitigated supply chains to compete on aworld stage. This should not wait until a drug has been registeredbut should start as early as possible in the development processand before registration or clinical trials. The author suggeststhat CMC (chemistry manufacturing controls) drug development mustreset the line of sight - from supply of drug to the clinicand gaining a registration, to the building of a patient valuestream. Capable processes and suppliers, streamlined logisticsflexible plant and equipment, shorter cycle times, effective flowof information and reduced waste. All these factors can and shouldbe addressed at the CMC development stage.

Kunden Rezensionen

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.